Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Sammons, Sarah L.
Meisel, Jane
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Targeted therapies for ER+/HER2- metastatic breast cancer
    Mutsuko Yamamoto-Ibusuki
    Monica Arnedos
    Fabrice André
    BMC Medicine, 13
  • [32] A Phase II Trial of Onapristone and Fulvestrant for Patients With ER + and HER2-Metastatic Breast Cancer
    Kamaraju, Sailaja
    Fowler, Amy M.
    Tarima, Sergey
    Chaudhary, Lubna N.
    Burkard, Mark E.
    Giever, Thomas
    Cheng, Yee C.
    Parkes, Amanda
    Lange, Carol A.
    Pipp-Dahm, Michele
    Hegeman, Robert
    Siddiqui, Nauman
    Stella, Amy
    Rajguru, Saurabh
    Twaroski, Kyleigh
    Zurbriggen, Luke
    Jorns, Julie M.
    Rui, Hallgeir
    Keigley, Quinton J.
    Perlman, Scott B.
    Salem, Kelley
    Bradshaw, Tyler J.
    Sahmoud, Tarek
    Wisinski, Kari
    CLINICAL BREAST CANCER, 2025, 25 (03) : 251 - 260
  • [33] Quality if life (QoL) improvements in patients (pts) with metastatic breast cancer (MBC) treated with capecitabine (X)
    Segalla, Jose
    Oliveira, Celia
    Lago, Sergio
    Cabral, Sebastiao
    Ribeiro, Ronaldo
    Perdicaris, Martha
    Abdo, E.
    Garicochea, B.
    Moore, F. C.
    Fabiani, C.
    ANNALS OF ONCOLOGY, 2004, 15 : 45 - 45
  • [34] Quality of life (QoL) improvements in patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X).
    Oliveira, C
    Beato, C
    Ribeiro, R
    Cabral, S
    Tessaro, S
    Lago, S
    Abdo, E
    Moura, G
    Perdicaris, M
    Garicochea, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 738S - 738S
  • [35] QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN TREATMENT WITH PLACITAXEL WITH/WITHOUT BEVACIZUMAB, RELATED WITH TREATMENT RESPONSE (REMISSION AND PROGRESSION)
    Tenorio, C.
    Vargas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A484 - A484
  • [36] SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study
    Chandarlapaty, S.
    Bardia, A.
    Lord, S.
    Linden, H.
    Pelekanou, V.
    Ternes, N.
    Ming, J.
    Boutet, V.
    Boitier, E.
    Gosselin, A.
    Lee, J. Sang
    Bele, W. Dos-Santos
    Protopopov, A.
    Celanovic, M.
    Bauchet, A-L.
    Campone, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S351 - S351
  • [37] Do body composition parameters correlate with response to targeted therapy in ER+/HER2-metastatic breast cancer patients? Role of sarcopenia and obesity
    Kripa, Endi
    Rizzo, Veronica
    Galati, Francesca
    Moffa, Giuliana
    Cicciarelli, Federica
    Catalano, Carlo
    Pediconi, Federica
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Sanders, Melinda
    Juric, Dejan
    Li, Yisheng
    Ley, Lewis Cant
    Winer, Eric P.
    Arteag, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Real-world treatment patterns and outcomes in ER+/PR+/HER2+metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
    Statler, Abby
    Nahleh, Zeina A.
    Hobbs, Brian
    Wei, Wei
    Gupta, Annie
    Blake, Cassann N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Is there a correlation between androgen receptor (AR) expression in metastatic breast cancer (MBC) ER+/Her2-and response to anti-estrogen treatment?
    Martinez, M. C. Riesco
    Hanna, W.
    Ghorab, Z.
    Warner, E.
    CANCER RESEARCH, 2013, 73
12345